Spondyloepiphyseal dysplasia congenita

Spondyloepiphyseal dysplasia congenita
Synonyms	SED congenita, Congenital spondyloepiphyseal dysplasia
Pronounce	/ˌspɒndɪloʊˌɛpɪˈfaɪziəl dɪsˈpleɪʒə/
Field	Medical genetics, Pediatrics, Orthopedics
Symptoms	Short trunk dwarfism, joint pain, scoliosis, clubfoot, vision and hearing problems
Complications	Spinal cord compression, early-onset arthritis, respiratory difficulties
Onset	At birth
Duration	Lifelong
Types	Congenital (SED congenita), tarda (later onset, often inherited X-linked)
Causes	Mutation in COL2A1 gene
Risks	Family history (autosomal dominant inheritance)
Diagnosis	Clinical features, radiographic findings, genetic testing
Differential diagnosis	Achondroplasia, Hypochondrogenesis, Spondyloepimetaphyseal dysplasia
Prevention	None (genetic condition)
Treatment	Supportive care, physical therapy, orthopedic surgery
Medication	Pain relief (NSAIDs)
Prognosis	Variable; most patients have normal lifespan but may have mobility issues
Frequency	Rare (<1 in 100,000)
Deaths	Rare, typically related to spinal cord complications

Spondyloepiphyseal dysplasia congenita (SED congenita) is a rare genetic disorder that affects the development of bones and connective tissue, particularly the spine and the ends (epiphyses) of long bones. This condition is present from birth and is associated with disproportionate short stature, skeletal abnormalities, and, in some cases, vision and hearing impairments. It belongs to the group of conditions known as osteochondrodysplasias.

Presentation

People with SED congenita are characteristically short in stature, with a disproportionately short trunk compared to the limbs. Additional clinical features include:

• Flattened vertebrae (platyspondyly)
• Kyphoscoliosis or lordosis (curvature of the spine)
• Limited joint mobility
• Early-onset osteoarthritis
• Coxa vara (inward angle of the femur)
• Clubfoot
• Cleft palate
• High myopia and increased risk of retinal detachment
• Mild to moderate hearing loss (sensorineural or conductive)

Although intelligence is typically normal, spinal instability and neurologic complications due to vertebral abnormalities may occur.

Cause

SED congenita is caused by mutations in the COL2A1 gene, which encodes the alpha-1 chain of type II collagen, a protein essential for the development of cartilage and the vitreous body of the eye. The mutation disrupts normal collagen formation, leading to defective bone and cartilage development.

This condition is inherited in an autosomal dominant manner, meaning only one copy of the mutated gene is sufficient to cause the disorder. Most cases result from de novo (new) mutations, but familial transmission can also occur.

Diagnosis

Diagnosis is based on:

• Clinical presentation of short stature and skeletal anomalies
• Radiographic evidence of spine and epiphyseal abnormalities (e.g., platyspondyly, delayed ossification)
• Molecular genetic testing confirming a mutation in COL2A1
• Eye and hearing assessments
• Differential diagnosis includes achondroplasia, hypochondrogenesis, and spondyloepimetaphyseal dysplasia

Management

There is no cure for SED congenita, but supportive management can greatly improve quality of life:

• Regular monitoring by a multidisciplinary team (genetics, orthopedics, ophthalmology, audiology)
• Physical therapy to enhance mobility and muscle strength
• Surgical intervention for spinal deformities, cleft palate, or hip abnormalities
• Use of mobility aids as needed
• Vision correction (glasses or surgery for retinal detachment)
• Hearing aids or cochlear implants in cases of hearing impairment

Prognosis

Life expectancy is generally normal, but complications such as spinal instability or respiratory difficulties can pose risks. Most individuals lead functional lives with appropriate management and intervention.

Epidemiology

SED congenita is a rare condition, with an estimated prevalence of less than 1 in 100,000 live births. It affects individuals of all ethnic backgrounds equally and is slightly more common in males due to more frequent diagnosis in males with skeletal anomalies.

History

The condition was first described in the early 20th century. It has since been classified as a type of collagenopathy, types II and XI, due to its association with type II collagen gene mutations.

See also

• Achondroplasia
• Spondyloepimetaphyseal dysplasia
• Dwarfism
• COL2A1
• Collagenopathy